Clinical Trial Finder

Inclusion Criteria:

• - Has unresectable Stage III or Stage IV or melanoma per American Joint Committee on Cancer (AJCC) staging system version 8.

• - No previously received systematic therapy.

• - The toxicity of prior treatment has recovered to ≤1 grade according to CTCAE 5.0.

• - ECOG score 0-1.

• - The expected survival time is ≥ 12 weeks.

• - Adequate organ and bone marrow function.

• - Female subjects of childbearing age must undergo a serum pregnancy test within 7 days before the commencement of the study and the results are negative, and are willing to use a medically approved high potency contraceptive method during the study period and within 3 months after the last administration of the study drug; For male subjects whose partner is a female of childbearing age, they should be surgically sterilized or agree to use an effective method of contraception during the study period and for 3 months after administration of the last study.

• - Willing to consent and signed the informed consent, and able comply with the planned visit, research treatment, laboratory examination and other test procedures.

Exclusion Criteria:

• - History of other malignant tumors, except for cured skin basal cell carcinoma, squamous cell carcinoma of skin, superficial bladder carcinoma, papillary thyroid carcinoma, intraductal carcinoma and cervical carcinoma in situ.

• - Has ocular melanoma.

• - The first study drug treatment was less than 4 weeks from the last systematic antitumor therapy or 5 half-lives from the last targeted therapy; less than 4 weeks from major surgery; less than7 days from immunosuppressive drug; less than 3 weeks from immunomodulatory; less than 4 weeks from live attenuated vaccine.

• - Systemic antibiotic use for 7 days within 4 weeks prior to initial administration, or unexplained fever during screening/prior to initial administration.

• - With active autoimmune disease or a history of autoimmune disease.

• - With history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation.

• - With immunodeficiency, eg HIV, HBV, HCV.

• - Have a clear history of serious and uncontrolled other disease or mental disorders.

• - Has a bleeding tendency or abnormal clotting function.

• - Subjects with central nervous system disease or brain metastases.

• - Known to be allergic to the active ingredients or excipients in this study.

• - Other situations that the researcher considers inappropriate to participate in the research.

This trial is a prospective, single-center, single-arm clinical research. Based on current experience, single agent immunotherapy has limited efficacy in advanced melanoma. SHR-1701 is a novel immunotherapy drug . Preclinical data suggest that temozolomide selectively depletes regulatory T cells. This potential immunomodulatory effect of temozolomide provides rationale for combination with SHR-1701. This study is aiming to evaluate the efficacy and safety of SHR-1701 combined with temozolomide in patients with advanced melanoma. The safety and efficacy of this study will be assessed through ORR, DCR,PFS, OS , and adverse effects as graded by CTCAE 5.0.

Arms

Interventions